Autres langues CanSino Biologics Inc.

Actions

6185

CNE100003F01

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:20 26/04/2024			Varia. 5j.	Varia. 1 janv.
18,82 ^HKD	+2,51%		+14,06%	-20,08%

21/03	Cansino Biologics débute les essais cliniques de phase III pour son médicament contre le tétanos	MT
20/03	Cansino Biologics Inc. annonce le lancement d'un essai clinique de phase III et l'obtention du premier cas de patient pour le vaccin antitétanique absorbé	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine	26/04
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	22/04
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results	22/04
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough	27/03
CanSino Biologics : CanSinoBIO Initiates Phase Ⅲ Clinical Trial of Group ACYW135 Meningococcal Conjugate Vaccine Menhycia® in Indonesia	25/03
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	21/03
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20/03
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute	14/03
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	28/02
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	26/02
Cansino Biologics Inc. Announces Board and Committee Elections	23/02
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
CanSino Biologics Deconsolidates CanSino SPH	02/02
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	31/01
CanSino Biologics' 13-Valent Pneumococcal Vaccine Trial Shows Positive Results	31/01
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	30/01
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	30/01
CanSino Biologics Enrols First Patient in Australia Clinical Trial of Polio Vaccine	15/01
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	15/01
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes	12/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

INTERVIEW - Xuefeng Yu, PDG de CanSino Biologics : Les coulisses de l'accord avec AstraZeneca

Le 31 août 2023 à 12:08